Skip to main content
CMND logo

Clearmind Medicine Inc. (CMND) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$3.04 -$0.025 (-0.82%)
MCap: $1.54M| Vol: 2.2K|

Market cap $1.54M is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Clearmind Medicine Inc. (CMND) trades at $3.04. Clearmind Medicine Inc. is a pre-clinical pharmaceutical company focused on developing novel psychedelic medicines for underserved health problems. Market cap: $1.54M, Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
Clearmind Medicine Inc. is a pre-clinical pharmaceutical company focused on developing novel psychedelic medicines for underserved health problems. The company targets treatments for alcohol use disorders, eating disorders, depression, and other mental health issues.

Analyst Coverage for CMND: CMND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CNSP · CNS Pharmaceuticals, Inc. · 32 /100
  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100

See all scored stocks →

Clearmind Medicine Inc. (CMND) Healthcare & Pipeline Overview

CEOAdi Zuloff-Shani
Employees4
HeadquartersVancouver, CA
IPO Year2022

Clearmind Medicine Inc., a pre-clinical stage biotechnology firm, is focused on developing psychedelic-based therapeutics for addiction and mental health disorders. With a pipeline targeting alcohol use disorder and binge eating, Clearmind operates in the emerging psychedelic medicine market, competing with other early-stage companies in the biotechnology sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for CMND?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Clearmind Medicine Inc. presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. The company's focus on developing treatments for addiction and mental health disorders addresses a significant unmet need, with the potential for substantial market demand if its therapies prove effective. Key value drivers include the successful completion of pre-clinical studies, the initiation of clinical trials, and the potential for regulatory approval of its psychedelic medicines. However, the company faces significant challenges, including the regulatory hurdles associated with psychedelic substances, the uncertainty of clinical trial outcomes, and the need to secure substantial funding to support its research and development efforts. As of 2026, the company has a market capitalization of $1.54M and a P/E ratio of -0.14. Upcoming catalysts include the progression of its drug candidates through the development pipeline. Potential risks include negative clinical trial results and increased competition in the psychedelic medicine space.

Based on FMP financials and quantitative analysis

CMND Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Clearmind Medicine Inc. is a pre-clinical stage pharmaceutical company focused on developing psychedelic medicines.

  • The company targets treatments for alcohol use disorders, eating disorders, depression, and other mental health issues.
  • Clearmind Medicine Inc. changed its name from Cyntar Ventures Inc. in March 2021.
  • The company is based in Vancouver, Canada.
  • The company has a market capitalization of $1.54M and a P/E ratio of -0.14.

Who Are CMND's Competitors?

CMND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CNSP CNS Pharmaceuticals, Inc. $3.92 -10.51% $5.78M 32 5-pillar
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar
FENC Fennec Pharmaceuticals Inc. $13.33 -1.84% $471M 91 5-pillar
INDP Indaptus Therapeutics, Inc. $3.13 -4.86% $481M 60 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CMND's Key Strengths?

Novel psychedelic medicine development.

  • Focus on underserved health problems.
  • Potential for strategic partnerships.
  • Experienced management team.

What Are CMND's Weaknesses?

Pre-clinical stage company.

  • Limited financial resources.
  • Dependence on regulatory approvals.
  • Small number of employees.

What Could Drive CMND Stock Higher?

Completion of pre-clinical studies for lead drug candidates.

  • Initiation of Phase 1 clinical trials.
  • Expansion of intellectual property portfolio.
  • Formation of strategic partnerships with pharmaceutical companies.

What Are the Key Risks for CMND?

Financial-distress signal — its Altman Z-Score of -3.12 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-87.3%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
  • Negative results from clinical trials.
  • Regulatory delays or rejection of drug candidates.
  • Competition from other companies in the psychedelic medicine space.
  • Dependence on securing additional funding to support research and development.

What Are the Growth Opportunities for CMND?

  • Advancement of Drug Pipeline: Clearmind's primary growth opportunity lies in successfully advancing its pipeline of psychedelic medicines through pre-clinical and clinical development. The company's focus on alcohol use disorders, eating disorders, and depression addresses significant unmet needs in the mental health market. Positive results from pre-clinical studies and clinical trials could lead to increased investor interest, strategic partnerships, and ultimately, regulatory approval and commercialization of its products. The timeline for this growth opportunity depends on the speed and success of the company's research and development efforts, with potential for initial clinical trial data within the next 2-3 years.
  • Strategic Partnerships and Collaborations: Clearmind can accelerate its growth by forming strategic partnerships with established pharmaceutical companies, research institutions, and other organizations. These collaborations can provide access to funding, expertise, and resources needed to advance its drug development programs. Partnerships can also facilitate the commercialization of its products and expand its market reach. The company is actively seeking partnerships to support its research and development efforts, with potential for new collaborations to be announced in the near future.
  • Expansion of Therapeutic Applications: Clearmind has the opportunity to expand the therapeutic applications of its psychedelic medicines beyond its initial targets. The company's research may uncover new uses for its compounds in treating other mental health disorders, neurological conditions, or other diseases. This expansion could significantly increase the market potential of its products and create new revenue streams. The company is continuously exploring new therapeutic applications for its psychedelic medicines, with potential for new indications to be identified in the coming years.
  • Intellectual Property Protection: Clearmind can strengthen its competitive position by securing intellectual property protection for its novel psychedelic medicines and related technologies. Patents and other forms of IP protection can provide the company with exclusive rights to its inventions, preventing competitors from copying its products and giving it a significant market advantage. The company is actively pursuing patent protection for its psychedelic medicines and related technologies, with potential for new patents to be granted in the near future.
  • Capitalizing on Regulatory Changes: The regulatory landscape for psychedelic medicines is evolving rapidly, with increasing acceptance of their potential therapeutic benefits. Clearmind can capitalize on these regulatory changes by working closely with regulatory agencies to ensure its products meet the required safety and efficacy standards. The company can also advocate for policies that support the development and use of psychedelic medicines. The timeline for this growth opportunity depends on the pace of regulatory reform, with potential for significant changes in the coming years.

What Threats Does CMND Face?

  • Regulatory hurdles.
  • Competition from other companies.
  • Uncertainty of clinical trial outcomes.
  • Negative public perception of psychedelics.

What Are CMND's Competitive Advantages?

  • Proprietary psychedelic compounds.
  • Intellectual property protection (patents).
  • Focus on underserved health problems.
  • Potential for strategic partnerships with pharmaceutical companies.

What Does CMND Do?

Clearmind Medicine Inc., formerly Cyntar Ventures Inc., was incorporated in 2017 and rebranded in March 2021 to reflect its focus on psychedelic medicine. Headquartered in Vancouver, Canada, the company is dedicated to developing novel treatments for a range of underserved health problems, particularly those related to addiction and mental health. Clearmind's research and development efforts are centered on creating pharmaceutical-grade psychedelic medicines designed to address conditions such as alcohol use disorders, including binge drinking, eating disorders, depression, binge eating, and other binge behaviors. The company operates as a pre-clinical pharmaceutical entity, meaning its primary activities revolve around research, drug discovery, and early-stage development. Clearmind's approach involves identifying and developing novel psychedelic compounds with the potential to treat the underlying causes of addiction and mental health disorders. The company aims to develop treatments that can be used in conjunction with psychotherapy to enhance the therapeutic effects and improve patient outcomes. Clearmind is currently focused on advancing its pipeline of psychedelic medicines through pre-clinical studies, with the goal of eventually initiating clinical trials to evaluate the safety and efficacy of its treatments in humans. The company's long-term strategy involves partnering with established pharmaceutical companies to commercialize its products and bring them to market.

What Products and Services Does CMND Offer?

  • Develops novel psychedelic medicines.
  • Targets treatments for alcohol use disorders.
  • Develops treatments for eating disorders.
  • Focuses on treatments for depression.
  • Addresses other mental health issues.
  • Conducts pre-clinical research and development.

How Does CMND Make Money?

  • Develops proprietary psychedelic compounds.
  • Conducts pre-clinical studies to evaluate safety and efficacy.
  • Seeks partnerships with pharmaceutical companies for clinical trials and commercialization.
  • Aims to obtain regulatory approval for its psychedelic medicines.

What Industry Does CMND Operate In?

Clearmind Medicine Inc. operates within the rapidly evolving biotechnology industry, specifically targeting the emerging market for psychedelic medicines. This market is driven by a growing recognition of the potential therapeutic benefits of psychedelic substances for treating mental health disorders and addiction. The industry is characterized by intense competition, with numerous companies vying to develop novel psychedelic therapies. Clearmind's success will depend on its ability to differentiate its products, navigate the complex regulatory landscape, and secure funding to support its research and development efforts. The global market for mental health treatments is estimated to reach $241.7 billion by 2027, indicating a significant opportunity for companies developing innovative therapies.

Who Are CMND's Key Customers?

  • Pharmaceutical companies seeking novel therapeutics.
  • Patients suffering from alcohol use disorders.
  • Patients suffering from eating disorders.
  • Patients suffering from depression.
  • Healthcare providers treating mental health issues.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Medium 60/100

Enough evidence to be useful, with gaps worth knowing about.

  • ● Scored on 91% of our measures
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Clearmind Medicine Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Adi Zuloff-Shani. CMND has traded publicly since 2022.

F-Score 1/9

Financial Health

Clearmind Medicine Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.12 places it in the distress zone, a signal of elevated financial risk.

ROE -87%

Key Financial Metrics

Return on equity for Clearmind Medicine Inc. stands at -87.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -44.3%, showing how much profit it generates from its asset base. A current ratio of 4.31 indicates the company holds enough short-term assets to cover its near-term obligations.

CMND Valuation & Market Position

With a $1.54M market cap, Clearmind Medicine Inc. sits in the micro-cap segment of the market.

Net buying

Insider Activity

5 transactions · 1 purchases, 4 sales, 0 other transactions · 1 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jun 16, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

CMND Financials

Bull Case vs Bear Case

Bull Case

  • Novel psychedelic medicine development.
  • Focus on underserved health problems.
  • Potential for strategic partnerships.
  • Experienced management team.

Bear Case

  • Pre-clinical stage company.
  • Limited financial resources.
  • Dependence on regulatory approvals.
  • Small number of employees.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · November 2026

CMND Latest News

CMND Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CMND.

Price Targets

Wall Street price target analysis for CMND.

CMND MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CMND; grades run from A+ (80-100) to F (below 30).

Leadership: Adi Zuloff-Shani

CEO

Adi Zuloff-Shani serves as the CEO of Clearmind Medicine Inc., bringing a wealth of experience in the pharmaceutical and biotechnology industries. Her background includes extensive work in drug development, clinical research, and regulatory affairs. Prior to joining Clearmind, she held leadership positions at several pharmaceutical companies, where she oversaw the development and commercialization of novel therapies. She has a strong track record of successfully navigating the complex regulatory landscape and bringing innovative products to market. Her expertise in strategic planning, business development, and financial management is instrumental in guiding Clearmind's growth and success.

Track Record: Under Adi Zuloff-Shani's leadership, Clearmind Medicine Inc. has made significant progress in advancing its pipeline of psychedelic medicines. She has overseen the expansion of the company's research and development efforts, the strengthening of its intellectual property portfolio, and the establishment of strategic partnerships with key stakeholders. Her focus on innovation and execution has positioned Clearmind as a leader in the emerging psychedelic medicine market.

CMND Healthcare Stock FAQ

Is CMND a good stock to buy?

Stock Expert AI does not rate CMND buy, sell or hold. Clearmind Medicine Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CMND stock price today?

The last price recorded on this page for Clearmind Medicine Inc. (CMND) is $3.04, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about CMND stock?

As of March 16, 2026, there is no available analyst coverage for Clearmind Medicine Inc. (CMND). Given its pre-clinical stage and small market capitalization, the company has yet to attract significant attention from institutional analysts.

What are the key factors to evaluate for CMND?

Evaluate CMND on fundamentals, analyst consensus, and risk factors. As of 2026, the company has a market capitalization of $1.54M and a P/E ratio of -0.14. Not financial advice.

How frequently does CMND data refresh on this page?

CMND's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CMND's recent stock price performance?

Clearmind Medicine Inc. (CMND) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel psychedelic medicine development. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CMND overvalued or undervalued right now?

Clearmind Medicine Inc. (CMND) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CMND before investing?

Before investing in Clearmind Medicine Inc. (CMND), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives